Prodrugs of phosphonates and phosphates: Crossing the membrane barrier

Topics in Current Chemistry

Volumn 360, Issue , 2015, Pages 115-160

  Wiemer, Andrew J ^a   Wiemer, David F ^b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Bisphosphonate; Isoprenoid; Nucleotide; Phosphate; Phosphonate; Prodrugs

Indexed keywords

ANTIVIRUS AGENT; ESTER; NUCLEOSIDE; NUCLEOTIDE; PHOSPHATE; PHOSPHONIC ACID DERIVATIVE; PRODRUG; PROTEIN; TERPENE;

ANIMAL; CELL MEMBRANE; CELL MEMBRANE PERMEABILITY; CYTOLOGY; DRUG DESIGN; DRUG EFFECTS; EUKARYOTIC CELL; HUMAN; METABOLISM; PHOSPHORYLATION; SYNTHESIS;

ANIMALS; ANTIVIRAL AGENTS; CELL MEMBRANE; CELL MEMBRANE PERMEABILITY; DRUG DESIGN; ESTERS; EUKARYOTIC CELLS; HUMANS; NUCLEOSIDES; NUCLEOTIDES; ORGANOPHOSPHONATES; PHOSPHATES; PHOSPHORYLATION; PRODRUGS; PROTEINS; TERPENES;

EID: 84924359638     PISSN: 03401022     EISSN: None     Source Type: Book Series    
DOI: 10.1007/128_2014_561     Document Type: Article

References (233)

1. Westheimer FH (1987) Why nature chose phosphates. Science 235: 1173-1178.
2. Engel R (1977) Phosphonates as analogs of natural phosphates. Chem Rev 77: 349-367.
3. Metcalf WW, van der Donk WA (2009) Biosynthesis of phosphonic and phosphinic acid natural products. Annu Rev Biochem 78: 65-94.
4. Williams R, Jencks WP, Westheimer FH (2001) Table of pKa values. http://research. chem. psu. edu/brpgroup/pKa_compilation. pdf. Accessed 14 Oct 2014.
5. Wiemer DF (1997) Synthesis of nonracemic phosphonates. Tetrahedron 53: 16609-16644.
6. Kornberg RD, McNamee MG, McConnell HM (1972) Measurement of transmembrane potentials in phospholipid vesicles. Proc Natl Acad Sci USA 69: 1508-1513.
7. Ghosh S, Chan JMW, Lea CR, Meints GA, Lewis JC, Tovian ZS, Flessner RM, Loftus TC, Bruchhaus I, Kendrick H et al (2004) Effects of bisphosphonates on the growth of Entamoeba histolytica and Plasmodium species in vitro and in vivo. J Med Chem 47: 175-187.
8. Huttunen KM, Rautio J (2011) Prodrugs-an efficient way to breach delivery and targeting barriers. Curr Top Med Chem 11: 2265-2287.
9. Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V (1995) Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 22: 3-10.
10. McGuigan C, Jones BCNM, Riley PA (1991) Trans-esterification reactions yield novel masked phosphate derivatives of the anti-cancer agent araC. Bioorg Med Chem Lett 1: 607-610.
11. Maiti M, Persoons L, Andrei G, Snoeck R, Balzarini J, Herdewijn P (2013) Synthesis and anti-herpetic activity of phosphoramidate ProTides. ChemMedChem 8: 985-993.
12. Krise JP, Stella VJ (1996) Prodrugs of phosphates, phosphonates, and phosphinates. Adv Drug Deliv Rev 19: 287-310.
13. Cho A (2006) Recent advances in oral prodrug discovery. Ann Rep Med Chem 41: 395-407.
14. He GX, Krise JP, Oliyai R (2007) Prodrugs of phosphonates, phosphinates, and phosphates. In: Stella VJ, Borchardt RT, Hageman MJ, Oliyai R, Maag H, Tilley JW (eds) Prodrugs: Challenges and Rewards. Part 2, Springer, New York, pp 923-964.
15. Meier C (1998) Pro-nucleotides-recent advances in the design of efficient tools for the delivery of biologically active nucleoside monophosphates. Synlett 233-242.
16. Mackman RL, Cihlar T (2004) Prodrug strategies in the design of nucleoside and nucleotide antiviral therapeutics. Ann Rep Med Chem 39: 305-321.
17. Ariza ME (2005) Current prodrug strategies for the delivery of nucleotides into cells. Drug Des Rev 2: 373-387.
18. Ray AS, Hostetler KY (2011) Application of kinase bypass strategies to nucleoside antivirals. Antiviral Res 92: 277-291.
19. Bobeck DR, Schinazi RF, Coats SJ (2010) Advances in nucleoside monophosphate prodrugs as anti-HCV agents. Antivir Ther 15: 935-950.
20. Madela K, McGuigan C (2012) Progress in the development of anti-hepatitis C virus nucleoside and nucleotide prodrugs. Fut Med Chem 4: 625-650.
21. Sofia MJ, Chang W, Furman PA, Mosley RT, Ross BS (2012) Nucleoside, nucleotide, and non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA-polymerase. J Med Chem 55: 2481-2531.
22. Hecker SJ, Erion MD (2008) Prodrugs of phosphates and phosphonates. J Med Chem 51: 2328-2345.
23. Greene TW, Wuts PGM (1991) Protective groups in organic synthesis, 2nd edn. Wiley, New York, NY.
24. Cho MJ, Kurtz RR, Lewis C, Machkovech SM, Houser DJ (1982) Metronidazole phosphate-a water-soluble prodrug for parenteral solutions of metronidazole. J Pharm Sci 71: 410-414.
25. Chung MC, Bosquesi PL, dos Santos JL (2011) A prodrug approach to improve the physicochemical properties and decrease the genotoxicity of nitro compounds. Curr Pharm Des 17: 3515-3526.
26. Palte MJ, Davis AKF, McGrath NA, Spiegel CA, Raines RT (2012) Ribonucleoside 3-0-phosphates as pro-moieties for an orally administered drug. ChemMedChem 7: 1361-1364.
27. Ellis GA, McGrath NA, Palte MJ, Raines RT (2012) Ribonuclease-activated cancer prodrug. ACS Med Chem Lett 3: 268-272.
28. O'Boyle NM, Greene LM, Keely NO, Wang S, Cotter TS, Zisterer DM, Meegan MJ (2013) Synthesis and biochemical activities of antiproliferative amino acid and phosphate derivatives of microtubule-disrupting beta-lactam combretastatins. Eur J Med Chem 62: 705-721.
29. Sweeny DJ, Li W, Clough J, Bhamidipati S, Singh R, Park G, Baluom M, Grossbard E, Lau DTW (2010) Metabolism of fostamatinib, the oral methylene phosphate prodrug of the spleen tyrosine kinase inhibitor R406 in humans: contribution of hepatic and gut bacterial processes to the overall biotransformation. Drug Metab Dispos 38: 1166-1176.
30. Gu Y, Atwell GJ, Wilson WR (2010) Metabolism and excretion of the novel bioreductive prodrug PR-104 in mice, rats, dogs, and humans. Drug Metab Dispos 38: 498-508.
31. Chou LC, Chen CT, Lee JC, Way TD, Huang CH, Huang SM, Teng CM, Yamori T, Wu TS, Sun CM et al (2010) Synthesis and preclinical evaluations of 2-(2-fluorophenyl)-6, 7-methylenedioxyquinolin-4-one monosodium phosphate (CHM-1-P-na) as a potent antitumor agent. J Med Chem 53: 1616-1626.
32. Ferriz JM, Vinsova J (2010) Prodrug design of phenolic drugs. Curr Pharm Des 16: 2033-2052.
33. Dhareshwar SS, Stella VJ (2010) A novel prodrug strategy for beta-dicarbonyl carbon acids: syntheses and evaluation of the physicochemical characteristics of C-phosphoryloxymethyl (POM) and phosphoryloxymethyloxymethyl (POMOM) prodrug derivatives. J Pharm Sci 99: 2711-2723.
34. Gotthard G, Hiblot J, Gonzalez D, Elias M, Chabriere E (2013) Structural and enzymatic characterization of the phosphotriesterase OPHC2 from pseudomonas pseudoalcaligenes. PLoS One 8: e77995.
35. Niemi R, Vepsalainen J, Taipale H, Jarvinen T (1999) Bisphosphonate prodrugs: synthesis and in vitro evaluation of novel acyloxyalkyl esters of clodronic acid. J Med Chem 42: 5053-5058.
36. Niemi R, Turhanen P, Vepsalainen J, Taipale H, Jarvinen T (2000) Bisphosphonate prodrugs: synthesis and in vitro evaluation of alkyl and acyloxymethyl esters of etidronic acid as bioreversible prodrugs of etidronate. Eur J Pharm Sci 11: 173-180.
37. Slatter JG, Feenstra KL, Hauer MJ, Kloosterman DA, Parton AH, Sanders PE, Scott G, Speed W (1996) Metabolism of the bisphosphonate ester U-91502 in rats. Drug Metab Dispos 24: 65-73.
38. Serafinowska HT, Ashton RJ, Bailey S, Harnden MR, Jackson SM, Sutton D (1995) Synthesis and in vivo evaluation of prodrugs of 9-[2-(phosphonomethoxy)ethoxy]adenine. J Med Chem 38: 1372-1379.
39. McGuigan C, Tollerfield SM, Riley PA (1989) Synthesis and biological evaluation of some phosphate triester derivatives of the anti-viral drug AraA. Nucleic Acids Res 17: 6065-6075.
40. Jones BCNM, McGuigan C, Riley PA (1989) Synthesis and biological evaluation of some phosphate triester derivatives of the anti-cancer drug AraC. Nucleic Acids Res 17: 7195-7201.
41. Lan S, Hsieh DC, Hillyer JW, Fancher RM, Rinehart KJ, Warrack BM, White RE (1998) Metabolism of α-phosphonosulfonate squalene synthase inhibitors. I. Disposition of a farnesylethyl α-phosphonosulfonate and ester prodrugs in rats. Drug Metab Dispos 26: 993-1000.
42. Dang Q, Liu Y, Rydzewski RM, Brown BS, Robinson E, van Poelje PD, Colby TJ, Erion MD (2007) Bis(para-methoxy)benzyl phosphonate prodrugs with improved stability and enhanced cell penetration. Bioorg Med Chem Lett 17: 3412-3416.
43. Dang Q, Brown BS, van Poelje PD, Colby TJ, Erion MD (1999) Synthesis of phosphonate 3-phthalidyl esters as prodrugs for potential intracellular delivery of phosphonates. Bioorg Med Chem Lett 9: 1505-1510.
44. Topczewski JJ, Neighbors JD, Wiemer DF (2009) Total synthesis of (+)-schweinfurthins B and E. J Org Chem 74: 6965-6972.
45. De Lombaert S, Erion MD, Tan J, Blanchard L, el-Chehabi L, Ghai RD, Sakane Y, Berry C, Trapani AJ (1994) N-Phosphonomethyl dipeptides and their phosphonate prodrugs, a new generation of neutral endopeptidase (NEP, EC 3. 4. 24. 11) inhibitors. J Med Chem 37: 498-511.
46. Romanowska J, Sobkowski M, Szymanska-Michalak A, Kolodziej K, Dabrowska A, Lipniacki A, Piasek A, Pietrusiewicz ZM, Figlerowicz M, Guranowski A et al (2011) Aryl H-phosphonates 17: (N-aryl)phosphoramidates of pyrimidine nucleoside analogues and their synthesis, selected properties, and anti-HIV activity. J Med Chem 54: 6482-6491.
47. Romanowska J, Szymanska-Michalak A, Boryski J, Stawinski J, Kraszewski A, Loddo R, Sanna G, Collu G, Secci B, La Colla P (2009) Aryl nucleoside H-phosphonates. part 16: synthesis and anti-HIV-1 activity of di-aryl nucleoside phosphotriesters. Bioorg Med Chem 17: 3489-3498.
48. De Clercq E, Holy A, Rosenberg I, Sakuma T, Balzarini J, Maudgal PC (1986) A novel selective broad-spectrum anti-DNA virus agent. Nature 323: 464-467.
49. Khandazhinskaya A, Yasko M, Shirokova E (2006) The synthesis and antiviral properties of acyclic nucleoside analogues with a phosphonomethoxy fragment in the side chain. Curr Med Chem 13: 2953-2980.
50. Farquhar D, Srivastva DN, Kattesch NJ, Saunders PP (1983) Biologically reversible phosphate-protective groups. J Pharm Sci 72: 324-325.
51. Srivastva DN, Farquhar D (1984) Bioreversible phosphate protective groups-synthesis and stability of model acyloxymethyl phosphates. Bioorg Chem 12: 118-129.
52. Iyer RP, Phillips LR, Biddle JA, Thakker DR, Egan W, Aoki S, Mitsuya H (1989) Synthesis of acyloxyalkyl acylphosphonates as potential prodrugs of the antiviral, trisodium phosphonoformate (foscarnet sodium). Tetrahedron Lett 30: 7141-7144.
53. Saperstein R, Vicario PP, Strout HV, Brady E, Slater EE, Greenlee WJ, Ondeyka DL, Patchett AA, Hangauer DG (1989) Design of a selective insulin receptor tyrosine kinase inhibitor and its effect on glucose uptake and metabolism in intact cells. Biochemistry 28: 5694-5701.
54. Lee WA, Martin JC (2006) Perspectives on the development of acyclic nucleotide analogs as antiviral drugs. Antiviral Res 71: 254-259.
55. Atack JR, Prior AM, Fletcher SR, Quirk K, McKernan R, Ragan CI (1994) Effects of L-690, 488, a prodrug of the bisphosphonate inositol monophosphatase inhibitor L-690, 330, on phosphatidylinositol cycle markers. J Pharmacol Exp Ther 270: 70-76.
56. Topalis D, Pradere U, Roy V, Caillat C, Azzouzi A, Broggi J, Snoeck R, Andrei G, Lin J, Eriksson S et al (2011) Novel antiviral C5-substituted pyrimidine acyclic nucleoside phosphonates selected as human thymidylate kinase substrates. J Med Chem 54: 222-232.
57. Naesens L, Bischofberger N, Augustijns P, Annaert P, Van den Mooter G, Arimilli MN, Kim CU, De Clercq E (1998) Antiretroviral efficacy and pharmacokinetics of oral bis(isopropyloxycarbonyloxymethyl)-9-(2-phosphonylmethoxypropyl)adenine in mice. Antimicrob Agents Chemother 42: 1568-1573.
58. Arimilli MN, Kim CU, Dougherty J, Mulato A, Oliyai R, Shaw JP, Cundy KC, Bischofberger N (1997) Synthesis, in vitro biological evaluation and oral bioavailability of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) prodrugs. Antivir Chem Chemother 8: 557-564.
59. De Clercq E, Holy A (2005) Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nat Rev Drug Discovery 4: 928-940.
60. Ripin DHB, Teager DS, Fortunak J, Basha SM, Bivins N, Boddy CN, Byrn S, Catlin KK, Houghton SR, Jagadeesh ST et al (2010) Process improvements for the manufacture of tenofovir disoproxil fumarate at commercial scale. Org Process Res Dev 14: 1194-1201.
61. Montagu A, Pradere U, Roy V, Nolan SP, Agrofoglio LA (2011) Expeditious convergent procedure for the preparation of bis(POC) prodrugs of new (E)-4-phosphono-but-2-en-1-yl nucleosides. Tetrahedron 67: 5319-5328.
62. Peyrottes S, Egron D, Lefebvre I, Gosselin G, Imbach JL, Perigaud C (2004) SATE pronucleotide approaches: an overview. Mini-Rev Med Chem 4: 395-408.
63. Oh CH, Liu LJ, Hong JH (2010) Design and synthesis of dually branched 50-norcarbocyclic adenosine phosphonodiester analogue as a new anti-HIV prodrug. Nucleosides Nucleotides Nucleic Acids 29: 721-733.
64. Liu LJ, Hong JH (2010) Design and synthesis of novel sate derivatives of acyclic isocytosine and 9-deazaadenine C-nucleosides. Nucleosides Nucleotides Nucleic Acids 29: 257-266.
65. Fu X, Ou Y, Pei J, Liu Y, Li J, Zhou W, Lan Y, Wang A, Wang Y (2012) Synthesis, anti-HBV activity and renal cell toxicity evaluation of mixed phosphonate prodrugs of adefovir. Eur J Med Chem 49: 211-218.
66. Meier C, Lorey M, De Clercq E, Balzarini J (1997) Cyclic saligenyl phosphotriesters of 20, 30-dideoxy-20, 30-didehydrothymidine (d4T)-a new pro-nucleotide approach. Bioorg Med Chem Lett 7: 99-104.
67. Meier C, Balzarini J (2006) Application of the cycloSal-prodrug approach for improving the biological potential of phosphorylated biomolecules. Antiviral Res 71: 282-292.
68. Meier C, Knispel T, De Clercq E, Balzarini J (1999) cycloSal-pronucleotides of 20, 3-0-dideoxyadenosine and 20, 30-dideoxy-20, 30-didehydroadenosine: synthesis and antiviral evaluation of a highly efficient nucleotide delivery system. J Med Chem 42: 1604-1614.
69. Meier C, Gorbig U, Muller C, Balzarini J (2005) cycloSal-PMEA and cycloAmb-PMEA: potentially new phosphonate prodrugs based on the cycloSal-pronucleotide approach. J Med Chem 48: 8079-8086.
70. Meier C, Ruppel MFH, Vukadinovic D, Balzarini J (2004) "Lock-in"-cycloSalpronucleotides-a new generation of chemical Trojan horses? Mini-Rev Med Chem 4: 383-394.
71. Gisch N, Balzarini J, Meier C (2007) 5-Diacetoxymethyl-cycloSal-d4TMP-a prototype of enzymatically activated cycloSal-pronucleotides. Nucleosides Nucleotides Nucleic Acids 26: 861-864.
72. Meier C, Lorey M, De Clercq E, Balzarini J (1998) cycloSal-20, 30-dideoxy-20, 30-didehydrothymidine monophosphate (cycloSal-d4TMP): synthesis and antiviral evaluation of a new d4TMP delivery system. J Med Chem 41: 1417-1427.
73. Morales EHR, Roman CA, Thomann JO, Meier C (2011) Linear synthesis of chiral cycloSalpronucleotides. Eur J Med Chem 2011: 4397-4408.
74. Rios Morales EH, Balzarini J, Meier C (2012) Stereoselective synthesis and antiviral activity of methyl-substituted cycloSal-pronucleotides. J Med Chem 55: 7245-7252.
75. Wolf S, Warnecke S, Ehrit J, Freiberger F, Gerardy-Schahn R, Meier C (2012) Chemical synthesis and enzymatic testing of CMP-sialic acid derivatives. Chembiochem 13: 2605-2615.
76. Huchting J, Ruthenbeck A, Meier C (2013) Synthesis of cycloSal-(glycopyranosyl-6)-phosphates as activated sugar phosphates. Eur J Org Chem 2013: 6907-6916.
77. Erion MD, Bullough DA, Lin C, Hong Z (2006) HepDirect prodrugs for targeting nucleotidebased antiviral drugs to the liver. Curr Opin Invest Drugs 7: 109-117.
78. Erion MD, Reddy KR, Boyer SH, Matelich MC, Gomez-Galeno J, Lemus RH, Ugarkar BG, Colby TJ, Schanzer J, Van Poelje PD (2004) Design, synthesis, and characterization of a series of cytochrome P(450) 3A-activated prodrugs (HepDirect prodrugs) useful for targeting phosph(on)ate-based drugs to the liver. J Am Chem Soc 126: 5154-5163.
79. Erion MD, van Poelje PD, Mackenna DA, Colby TJ, Montag AC, Fujitaki JM, Linemeyer DL, Bullough DA (2005) Liver-targeted drug delivery using HepDirect prodrugs. J Pharmacol Exp Ther 312: 554-560.
80. Boyer SH, Sun Z, Jiang H, Esterbrook J, Gomez-Galeno JE, Craigo W, Reddy KR, Ugarkar BG, MacKenna DA, Erion MD (2006) Synthesis and characterization of a novel livertargeted prodrug of cytosine-1-beta-D-arabinofuranoside monophosphate for the treatment of hepatocellular carcinoma. J Med Chem 49: 7711-7720.
81. Hecker SJ, Reddy KR, van Poelje PD, Sun Z, Huang W, Varkhedkar V, Reddy MV, Fujitaki JM, Olsen DB, Koeplinger KA et al (2007) Liver-targeted prodrugs of 20-C-methyladenosine for therapy of hepatitis C virus infection. J Med Chem 50: 3891-3896.
82. Bookser BC, Raffaele NB, Reddy KR, Fan K, Huang W, Erion MD (2009) Synthesis of 30-amino-30-deoxyguanosine and 30-amino-30-deoxyxyloguanosine monophosphate HepDirect prodrugs from guanosine. Nucleosides Nucleotides Nucleic Acids 28: 969-986.
83. Erion MD, Cable EE, Ito BR, Jiang H, Fujitaki JM, Finn PD, Zhang BH, Hou J, Boyer SH, van Poelje PD et al (2007) Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index. Proc Natl Acad Sci USA 104: 15490-15495.
84. Boyer SH, Jiang H, Jacintho JD, Reddy MV, Li H, Li W, Godwin JL, Schulz WG, Cable EE, Hou J et al (2008) Synthesis and biological evaluation of a series of liver-selective phosphonic acid thyroid hormone receptor agonists and their prodrugs. J Med Chem 51: 7075-7093.
85. Tsukada T, Tamaki K, Tanaka J, Takagi T, Yoshida T, Okuno A, Shiiki T, Takahashi M, Nishi T (2010) A prodrug approach towards the development of tricyclic-based FBPase inhibitors. Bioorg Med Chem Lett 20: 2938-2941.
86. Huttunen KM, Tani N, Juvonen RO, Raunio H, Rautio J (2013) Design, synthesis, and evaluation of novel cyclic phosphates of 5-aminosalicylic acid as cytochrome p450-activated prodrugs. Mol Pharm 10: 532-537.
87. Sun W, Peng W, Li G, Jiang T (2011) Design, synthesis, and sustained-release property of 1, 3-cyclic propanyl phosphate ester of 18 beta-glycyrrhetinic acid. Chem Biol Drug Des 77: 206-211.
88. Remy DC, Sunthankar AV, Heidelberger C (1962) Studies on fluorinated pyrimidines. XIV. The synthesis of derivatives of 5-fluoro-20-deoxyuridine 50-phosphate and related compounds. J Org Chem 27: 2491-2500.
89. Mukherjee KL, Heidelberger C (1962) Studies of fluorinated pyrimidines. XV. Inhibition of the incorporation of formate-C14 into DNA thymine of ehrlich ascites carcinoma cells by 5-fluoro-20-deoxyuridine-50-monophosphate and related compounds. Cancer Res 22: 815-822.
90. De Napoli L, Di Fabio G, D'Onofrio J, Montesarchio D (2005) An efficient solid phase synthesis of 50-phosphodiester and phosphoramidate monoester nucleoside analogues. Chem Commun 2586-2588.
91. Hostetler KY (2009) Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art. Antiviral Res 82: A84-A98.
92. Hostetler KY (2010) Synthesis and early development of hexadecyloxypropyl-cidofovir: an oral antipoxvirus nucleoside phosphonate. Viruses-Basel 2: 2213-2225.
93. Hostetler KY, Parker S, Sridhar CN, Martin MJ, Li JL, Stuhmiller LM, van Wijk GMT, van den Bosch H, Gardner MF, Aldern KA et al (1993) Acyclovir diphosphate dimyristoylglycerol-a phospholipid prodrug with activity against acyclovir-resistant herpes-simplex virus. Proc Natl Acad Sci USA 90: 11835-11839.
94. Hostetler KY, Beadle JR, Kini GD, Gardner MF, Wright KN, Wu TH, Korba BA (1997) Enhanced oral absorption and antiviral activity of 1-O-octadecyl-sn-glycero-3-phospho-acyclovir and related compounds in hepatitis B virus infection, in vitro. Biochem Pharmacol 53: 1815-1822.
95. Ciesla S, Trahan J, Wan W, Beadle J, Aldern K, Painter G, Hostetler K (2003) Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. Antiviral Res 59: 163-171.
96. Hostetler KY, Aldern KA, Wan WB, Ciesla SL, Beadle JR (2006) Alkoxyakl esters of (S)-9-[3-hydroxy-2-(phosphonomethoxy)propyl] adenine are potent inhibitors of the replication of wild-type and drug-resistant human immunodeficiency virus type 1 in vitro. Antimicrob Agents Chemother 50: 2857-2859.
97. Dal Pozzo F, Andrei G, Lebeau I, Beadle JR, Hostetler KY, De Clercq E, Snoeck R (2007) In vitro evaluation of the anti-orf virus activity of alkoxyalkyl esters of CDV, cCDV and (S)-HPMPA. Antiviral Res 75: 52-57.
98. Williams-Aziz SL, Hartline CB, Harden EA, Daily SL, Prichard MN, Kushner NL, Beadle JR, Wan WB, Hostetler KY, Kern ER (2005) Comparative activities of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro. Antimicrob Agents Chemother 49: 3724-3733.
99. Marty FM, Winston DJ, Rowley SD, Vance E, Papanicolaou GA, Mullane KM, Brundage TM, Robertson AT, Godkin S, Mommeja-Marin H et al (2013) CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med 369: 1227-1236.
100. Valiaeva N, Wyles DL, Schooley RT, Hwu JB, Beadle JR, Prichard MN, Hostetler KY (2011) Synthesis and antiviral evaluation of 9-(S)-[3-alkoxy-2-(phosphonomethoxy)propyl]nucleoside alkoxyalkyl esters: inhibitors of hepatitis C virus and HIV-1 replication. Bioorg Med Chem 19: 4616-4625.
101. Dong SD, Lin C, Schroeder M (2013) Synthesis and evaluation of a new phosphorylated ribavirin prodrug. Antiviral Res 99: 18-26.
102. Krylov IS, Kashemirov BA, Hilfinger JM, McKenna CE (2013) Evolution of an amino acid based prodrug approach: stay tuned. Mol Pharm 10: 445-458.
103. Oliyai R, Shaw JP, Sueoka-Lennen CM, Cundy KC, Arimilli MN, Jones RJ, Lee WA (1999) Aryl ester prodrugs of cyclic HPMPC. I: PhysicochemicaI characterization and in vitro biological stability. Pharm Res 16: 1687-1693.
104. Oliyai R, Arimilli MN, Jones RJ, Lee WA (2001) Pharmacokinetics of salicylate ester prodrugs of cyclic HPMPC in dogs. Nucleosides Nucleotides Nucleic Acids 20: 1411-1414.
105. Ruiz J, Beadle JR, Buller RM, Schreiwer J, Prichard MN, Keith KA, Lewis KC, Hostetler KY (2011) Synthesis, metabolic stability and antiviral evaluation of various alkoxyalkyl esters of cidofovir and 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine. Bioorg Med Chem 19: 2950-2958.
106. Keith KA, Wan WB, Ciesla SL, Beadle JR, Hostetler KY, Kern ER (2004) Inhibitory activity of alkoxyalkyl and alkyl esters of cidofovir and cyclic cidofovir against orthopoxvirus replication in vitro. Antimicrob Agents Chemother 48: 1869-1871.
107. Lebeau I, Andrei G, Dal Pozzo F, Beadle JR, Hostetler KY, De Clercq E, van den Oord J, Snoeck R (2006) Activities of alkoxvalkyl esters of cidofovir (CDV), cyclic CDV, and (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine against orthopoxviruses in cell monolayers and in organotypic cultures. Antimicrob Agents Chemother 50: 2525-2529.
108. McKenna CE, Kashemirov BA, Eriksson U, Amidon GL, Kish PE, Mitchell S, Kim JS, Hilfinger JM (2005) Cidofovir peptide conjugates as prodrugs. J Organomet Chem 690: 2673-2678.
109. Eriksson U, Peterson LW, Kashemirov BA, Hilfinger JM, Drach JC, Borysko KZ, Breitenbach JM, Kim JS, Mitchell S, Kijek P et al (2008) Serine peptide phosphoester prodrugs of cyclic cidofovir: synthesis, transport, and antiviral activity. Mol Pharm 5: 598-609.
110. Peterson LW, Sala-Rabanal M, Krylov IS, Serpi M, Kashemirov BA, McKenna CE (2010) Serine side chain-linked peptidomimetic conjugates of cyclic HPMPC and HPMPA: synthesis and interaction with hPEPT1. Mol Pharm 7: 2349-2361.
111. Zakharova VM, Serpi M, Krylov IS, Peterson LW, Breitenbach JM, Borysko KZ, Drach JC, Collins M, Hilfinger JM, Kashemirov BA et al (2011) Tyrosine-based 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine and-adenine ((S)-HPMPC and (S)-HPMPA) prodrugs: synthesis, stability, antiviral activity, and in vivo transport studies. J Med Chem 54: 5680-5693.
112. Krecmerova M, Holy A, Andrei G, Pomeisl K, Tichy T, Brehova P, Masojidkova M, Dracinsky M, Pohl R, Laflamme G et al (2010) Synthesis of ester prodrugs of 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-2, 6-diaminopurine (HPMPDAP) as anti-poxvirus agents. J Med Chem 53: 6825-6837.
113. Reddy PG, Bao D, Chang W, Chun B, Du J, Nagarathnam D, Rachakonda S, Ross BS, Zhang H, Bansal S et al (2010) 20-Deoxy-20-alpha-fluoro-20-beta-C-methyl 30, 50-cyclic phosphate nucleotide prodrug analogs as inhibitors of HCV NS5B polymerase: discovery of PSI-352938. Bioorg Med Chem Lett 20: 7376-7380.
114. Du J, Bao D, Chun B, Jiang Y, Reddy PG, Zhang H, Ross BS, Bansal S, Bao H, Espiritu C et al (2012) Beta-D-20-alpha-F-20-beta-C-methyl-6-O-substituted 30, 50-cyclic phosphate nucleotide prodrugs as inhibitors of hepatitis C virus replication: a structure-activity relationship study. Bioorg Med Chem Lett 22: 5924-5929.
115. Reddy PG, Chun B, Zhang H, Rachakonda S, Ross BS, Sofia MJ (2011) Stereoselective synthesis of PSI-352938: a beta-D-20-deoxy-20-alpha-fluoro-20-beta-C-methyl-30, 50-cyclic phosphate nucleotide prodrug for the treatment of HCV. J Org Chem 76: 3782-3790.
116. Mehellou Y, Balzarini J, McGuigan C (2009) Aryloxy phosphoramidate triesters: a technology for delivering monophosphorylated nucleosides and sugars into cells. Chemmedchem 4: 1779-1791.
117. Devine KG, McGuigan C, O'Connor TJ, Nicholls SR, Kinchington D (1990) Novel phosphate derivatives of zidovudine as anti-HIV compounds. AIDS 4: 371-373.
118. Pertusati F, Serpi M, McGuigan C (2012) Medicinal chemistry of nucleoside phosphonate prodrugs for antiviral therapy. Antivir Chem Chemother 22: 181-203.
119. McGuigan C, Bourdin C, Derudas M, Hamon N, Hinsinger K, Kandil S, Madela K, Meneghesso S, Pertusati F, Serpi M et al (2013) Design, synthesis and biological evaluation of phosphorodiamidate prodrugs of antiviral and anticancer nucleosides. Eur J Med Chem 70: 326-340.
120. McGuigan C, Madela K, Aljarah M, Bourdin C, Arrica M, Barrett E, Jones S, Kolykhalov A, Bleiman B, Bryant KD et al (2011) Phosphorodiamidates as a promising new phosphate prodrug motif for antiviral drug discovery: application to anti-HCV agents. J Med Chem 54: 8632-8645.
121. Jansa P, Baszczynski O, Dracinsky M, Votruba I, Zidek Z, Bahador G, Stepan G, Cihlar T, Mackman R, Holy A et al (2011) A novel and efficient one-pot synthesis of symmetrical diamide (bis-amidate) prodrugs of acyclic nucleoside phosphonates and evaluation of their biological activities. Eur J Med Chem 46: 3748-3754.
122. Erion MD, van Poelje PD, Dang Q, Kasibhatla SR, Potter SC, Reddy MR, Reddy KR, Jiang T, Lipscomb WN (2005) MB06322 (CS-917): a potent and selective inhibitor of fructose 1, 6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes. Proc Natl Acad Sci USA 102: 7970-7975.
123. Dang Q, Liu Y, Cashion DK, Kasibhatla SR, Jiang T, Taplin F, Jacintho JD, Li H, Sun Z, Fan Y et al (2011) Discovery of a series of phosphonic acid-containing thiazoles and orally bioavailable diamide prodrugs that lower glucose in diabetic animals through inhibition of fructose-1, 6-bisphosphatase. J Med Chem 54: 153-165.
124. van Poelje PD, Potter SC, Erion MD (2011) Fructose-1, 6-bisphosphatase inhibitors for reducing excessive endogenous glucose production in type 2 diabetes. Handb Exp Pharmacol 203: 279-301.
125. Pertusati F, Hinsinger K, Flynn ÁS, Powell N, Tristram A, Balzarini J, McGuigan C (2014) PMPA and PMEA prodrugs for the treatment of HIV infections and human papillomavirus (HPV) associated neoplasia and cancer. Eur J Med Chem 78: 259-268.
126. Saboulard D, Naesens L, Cahard D, Salgado A, Pathirana R, Velazquez S, McGuigan C, De Clercq E, Balzarini J (1999) Characterization of the activation pathway of phosphoramidate triester prodrugs of stavudine and zidovudine. Mol Pharmacol 56: 693-704.
127. Lee WA, He GX, Eisenberg E, Cihlar T, Swaminathan S, Mulato A, Cundy KC (2005) Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob Agents Chemother 49: 1898-1906.
128. Eisenberg EJ, He GX, Lee WA (2001) Metabolism of GS-7340, a novel phenyl monophosphoramidate intracellular prodrug of PMPA, in blood. Nucleosides Nucleotides Nucleic Acids 20: 1091-1098.
129. Ballatore C, McGuigan C, De Clercq E, Balzarini J (2001) Synthesis and evaluation of novel amidate prodrugs of PMEA and PMPA. Bioorg Med Chem Lett 11: 1053-1056.
130. McGuigan C, Hassan-Abdallah A, Srinivasan S, Wang Y, Siddiqui A, Daluge SM, Gudmundsson KS, Zhou H, McLean EW, Peckham JP et al (2006) Application of phosphoramidate ProTide technology significantly improves antiviral potency of carbocyclic adenosine derivatives. J Med Chem 49: 7215-7226.
131. Leisvuori A, Aiba Y, Lonnberg T, Poijarvi-Virta P, Blatt L, Beigelman L, Lonnberg H (2010) Chemical and enzymatic stability of amino acid derived phosphoramidates of antiviral nucleoside 50-monophosphates bearing a biodegradable protecting group. Org Biomol Chem 8: 2131-2141.
132. McGuigan C, Murziani P, Slusarczyk M, Gonczy B, Vande Voorde J, Liekens S, Balzarini J (2011) Phosphoramidate ProTides of the anticancer agent FUDR successfully deliver the preformed bioactive monophosphate in cells and confer advantage over the parent nucleoside. J Med Chem 54: 7247-7258.
133. Mehellou Y, Valente R, Mottram H, Walsby E, Mills KI, Balzarini J, McGuigan C (2010) Phosphoramidates of 20-beta-D-arabinouridine (AraU) as phosphate prodrugs; design, synthesis, in vitro activity and metabolism. Bioorg Med Chem 18: 2439-2446.
134. McGuigan C, Derudas M, Gonczy B, Hinsinger K, Kandil S, Pertusati F, Serpi M, Snoeck R, Andrei G, Balzarini J et al (2014) ProTides of N-(3-(5-(20-deoxyuridine))prop-2-ynyl) octanamide as potential anti-tubercular and anti-viral agents. Bioorg Med Chem 22: 2816-2824.
135. Perrone P, Luoni GM, Kelleher MR, Daverio F, Angell A, Mulready S, Congiatu C, Rajyaguru S, Martin JA, Leveque V et al (2007) Application of the phosphoramidate ProTide approach to 40-azidouridine confers sub-micromolar potency versus hepatitis C virus on an inactive nucleoside. J Med Chem 50: 1840-1849.
136. Vanpouille C, Lisco A, Derudas M, Saba E, Grivel JC, Brichacek B, Scrimieri F, Schinazi R, Schols D, McGuigan C et al (2010) A new class of dual-targeted antivirals: monophosphorylated acyclovir prodrug derivatives suppress both human immunodeficiency virus type 1 and herpes simplex virus type 2. J Infect Dis 201: 635-643.
137. Ruda GF, Wong PE, Alibu VP, Norval S, Read KD, Barrett MP, Gilbert IH (2010) Aryl phosphoramidates of 5-phospho erythronohydroxamic acid, a new class of potent trypanocidal compounds. J Med Chem 53: 6071-6078.
138. Vernachio JH, Bleiman B, Bryant KD, Chamberlain S, Hunley D, Hutchins J, Ames B, Gorovits E, Ganguly B, Hall A et al (2011) INX-08189, a phosphoramidate prodrug of 6-Omethyl-20-C-methyl guanosine, is a potent inhibitor of hepatitis C virus replication with excellent pharmacokinetic and pharmacodynamic properties. Antimicrob Agents Chemother 55: 1843-1851.
139. McGuigan C, Perrone P, Madela K, Neyts J (2009) The phosphoramidate ProTide approach greatly enhances the activity of beta-20-C-methylguanosine against hepatitis C virus. Bioorg Med Chem Lett 19: 4316-4320.
140. McGuigan C, Madela K, Aljarah M, Gilles A, Battina SK, Ramamurty CVS, Srinivas Rao C, Vernachio J, Hutchins J, Hall A et al (2011) Dual pro-drugs of 20-C-methyl guanosine monophosphate as potent and selective inhibitors of hepatitis C virus. Bioorg Med Chem Lett 21: 6007-6012.
141. Liederer BM, Borchardt RT (2006) Enzymes involved in the bioconversion of ester-based prodrugs. J Pharm Sci 95: 1177-1195.
142. Lim SM, Westover KD, Ficarro SB, Harrison RA, Choi HG, Pacold ME, Carrasco M, Hunter J, Kim ND, Xie T et al (2014) Therapeutic targeting of oncogenic K-ras by a covalent catalytic site inhibitor. Angew Chem Int Ed 53: 199-204.
143. Tobias SC, Borch RF (2001) Synthesis and biological studies of novel nucleoside phosphoramidate prodrugs. J Med Chem 44: 4475-4480.
144. Tobias SC, Borch RF (2004) Synthesis and biological evaluation of a cytarabine phosphoramidate prodrug. Mol Pharm 1: 112-116.
145. Lu P, Liu J, Wang Y, Chen X, Yang Y, Ji R (2009) Design, synthesis and evaluation of novel oxazaphosphorine prodrugs of 9-(2-phosphonomethoxyethyl)adenine (PMEA, adefovir) as potent HBV inhibitors. Bioorg Med Chem Lett 19: 6918-6921.
146. Gardelli C, Attenni B, Donghi M, Meppen M, Pacini B, Harper S, Di Marco A, Fiore F, Giuliano C, Pucci V et al (2009) Phosphoramidate prodrugs of 2 '-C-methylcytidine for therapy of hepatitis C virus infection. J Med Chem 52: 5394-5407.
147. Valette G, Pompon A, Girardet JL, Cappellacci L, Franchetti P, Grifantini M, La Colla P, Loi AG, Perigaud C, Gosselin G et al (1996) Decomposition pathways and in vitro HIV inhibitory effects of isoddA pronucleotides: toward a rational approach for intracellular delivery of nucleoside 50-monophosphates. J Med Chem 39: 1981-1990.
148. Grajkowski A, Ausin C, Kauffman JS, Snyder J, Hess S, Lloyd JR, Beaucage SL (2007) Solid-phase synthesis of thermolytic DNA oligonucleotides functionalized with a single 4-hydroxy-1-butyl or 4-phosphato-/thiophosphato-1-butyl thiophosphate protecting group. J Org Chem 72: 805-815.
149. Ausin C, Grajkowski A, Cieslak J, Gapeev A, Beaucage SL (2010) Time-dependent thermocontrol of the hydrophilic and lipophilic properties of DNA oligonucleotide prodrugs. Curr Protoc Nucleic Acid Chem 4: 42.
150. Kiuru E, Ahmed Z, Lonnberg H, Beigelman L, Ora M (2013) 2, 2-Disubstituted 4-acylthio-3-oxobutyl groups as esterase-and thermolabile protecting groups of phosphodiesters. J Org Chem 78: 950-959.
151. Ora M, Mantyvaara A, Lonnberg H (2011) 3-Acetyloxy-2-cyano-2-(alkylaminocarbamoyl) propyl groups as biodegradable protecting groups of nucleoside 50-mono-phosphates. Molecules 16: 552-566.
152. Farquhar D, Khan S, Srivastva DN, Saunders PP (1994) Synthesis and antitumor evaluation of bis[(pivaloyloxy)methyl] 20-deoxy-5-fluorouridine 50-monophosphate (FdUMP): a strategy to introduce nucleotides into cells. J Med Chem 37: 3902-3909.
153. Dickson JK, Biller SA, Magnin DR, Petrillo EW, Hillyer JW, Hsieh DC, Lan SJ, Rinehart JK, Gregg RE, Harrity TW et al (1996) Orally active squalene synthase inhibitors: bis((acyloxy) alkyl) prodrugs of the alpha-phosphonosulfonic acid moiety. J Med Chem 39: 661-664.
154. Aldern KA, Ciesla SL, Winegarden KL, Hostetler KY (2003) Increased antiviral activity of 1-O-hexadecyloxypropyl-[2-(14)C] cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism. Mol Pharmacol 63: 678-681.
155. Tehler U, Nelson CH, Peterson LW, Provoda CJ, Hilfinger JM, Lee KD, McKenna CE, Amidona GL (2010) Puromycin-sensitive aminopeptidase: an antiviral prodrug activating enzyme. Antiviral Res 85: 482-489.
156. Mendel DB, Cihlar T, Moon K, Chen MS (1997) Conversion of 1-[((S)-2-hydroxy-2-oxo-1, 4, 2-dioxaphosphorinan-5-yl)methyl]cytosine to cidofovir by an intracellular cyclic CMP phosphodiesterase. Antimicrob Agents Chemother 41: 641-646.
157. Schneider E, Kuhn M, Reinecke D, Wolter S, Burhenne H, Kaever V, Seifert R (2013) Fishing for elusive cCMP-degrading phosphodiesterases. BMC Pharmacol Toxicol 14: 1-2.
158. Gisch N, Balzarini J, Meier C (2007) Enzymatically activated cycloSal-d4Tmonophosphates: the third generation of cycloSal-pronucleotides. J Med Chem 50: 1658-1667.
159. Birkus G, Kutty N, He GX, Mulato A, Lee W, McDermott M, Cihlar T (2008) Activation of 9-[(R)-2-[[(S)-[[(S)-1-(isopropoxycarbonyl)ethyl]amino] phenoxyphosphinyl]-methoxy]propyl] adenine (GS-7340) and other tenofovir phosphonoamidate prodrugs by human proteases. Mol Pharmacol 74: 92-100.
160. Furman PA, Murakami E, Niu C, Lam AM, Espiritu C, Bansal S, Bao H, Tolstykh T, Steuer HM, Keilman M et al (2011) Activity and the metabolic activation pathway of the potent and selective hepatitis C virus pronucleotide inhibitor PSI-353661. Antiviral Res 91: 120-132.
161. Ray AS, Vela JE, Boojamra CG, Zhang L, Hui H, Callebaut C, Stray K, Lin KY, Gao Y, Mackman RL et al (2008) Intracellular metabolism of the nucleotide prodrug GS-9131, a potent anti-human immunodeficiency virus agent. Antimicrob Agents Chemother 52: 648-654.
162. Mackman RL, Ray AS, Hui HC, Zhang L, Birkus G, Boojamra CG, Desai MC, Douglas JL, Gao Y, Grant D et al (2010) Discovery of GS-9131: design, synthesis and optimization of amidate prodrugs of the novel nucleoside phosphonate HIV reverse transcriptase (RT) inhibitor GS-9148. Bioorg Med Chem 18: 3606-3617.
163. Lonnberg T, Ora M, Lonnberg H (2010) Hydrolytic reactions of nucleoside phosphoramidates: kinetics and mechanisms. Mini-Rev Org Chem 7: 33-43.
164. Murakami E, Tolstykh T, Bao H, Niu C, Micolochick Steuer HM, Bao D, Chang W, Espiritu C, Bansal S, Lam AM et al (2010) Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977. J Biol Chem 285: 34337-34347.
165. Chou TF, Baraniak J, Kaczmarek R, Zhou X, Cheng J, Ghosh B, Wagner CR (2007) Phosphoramidate pronucleotides: a comparison of the phosphoramidase substrate specificity of human and escherichia coli histidine triad nucleotide binding proteins. Mol Pharm 4: 208-217.
166. Birkus G, Wang R, Liu X, Kutty N, MacArthur H, Cihlar T, Gibbs C, Swaminathan S, Lee W, McDermott M (2007) Cathepsin A is the major hydrolase catalyzing the intracellular hydrolysis of the antiretroviral nucleotide phosphonoamidate prodrugs GS-7340 and GS-9131. Antimicrob Agents Chemother 51: 543-550.
167. Eichenbaum G, Skibbe J, Parkinson A, Johnson MD, Baumgardner D, Ogilvie B, Usuki E, Tonelli F, Holsapple J, Schmitt-Hoffmann A (2012) Use of enzyme inhibitors to evaluate the conversion pathways of ester and amide prodrugs: a case study example with the prodrug ceftobiprole medocaril. J Pharm Sci 101: 1242-1252.
168. Rhee SG (2013) Reflections on the days of phospholipase C. Adv Biol Regul 53: 223-231.
169. Baylon JL, Lenov IL, Sligar SG, Tajkhorshid E (2013) Characterizing the membrane-bound state of cytochrome P450 3A4: structure, depth of insertion, and orientation. J Am Chem Soc 135: 8542-8551.
170. Weiske J, Huber O (2005) The histidine triad protein Hint1 interacts with pontin and reptin and inhibits TCF-beta-catenin-mediated transcription. J Cell Sci 118: 3117-3129.
171. Birkus G, Kutty N, Frey CR, Shribata R, Chou T, Wagner C, McDermott M, Cihlar T (2011) Role of cathepsin A and lysosomes in the intracellular activation of novel antipapillomavirus agent GS-9191. Antimicrob Agents Chemother 55: 2166-2173.
172. Korboukh I, Hull-Ryde EA, Rittiner JE, Randhawa AS, Coleman J, Fitzpatrick BJ, Setola V, Janzen WP, Frye SV, Zylka MJ et al (2012) Orally active adenosine A(1) receptor agonists with antinociceptive effects in mice. J Med Chem 55: 6467-6477.
173. Kumar TS, Yang T, Mishra S, Cronin C, Chakraborty S, Shen JB, Liang BT, Jacobson KA (2013) 50-Phosphate and 50-phosphonate ester derivatives of (N)-methanocarba adenosine with in vivo cardioprotective activity. J Med Chem 56: 902-914.
174. Mehellou Y (2010) Phosphoramidate prodrugs deliver with potency against hepatitis C virus. Chemmedchem 5: 1841-1842.
175. Donnell D, Baeten JM, Bumpus NN, Brantley J, Bangsberg DR, Haberer JE, Mujugira A, Mugo N, Ndase P, Hendrix C et al. (2014) HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr 66: 340-348.
176. Chang W, Bao D, Chun BK, Naduthambi D, Nagarathnam D, Rachakonda S, Reddy PG, Ross BS, Zhang H, Bansal S et al (2011) Discovery of PSI-353661, a novel purine nucleotide prodrug for the treatment of HCV infection. ACS Med Chem Lett 2: 130-135.
177. Du J, Chun B, Mosley RT, Bansal S, Bao H, Espiritu C, Lam AM, Murakami E, Niu C, Micolochick Steuer HM et al (2014) Use of 20-spirocyclic ethers in HCV nucleoside design. J Med Chem 57: 1826-1835.
178. Jordheim LP, Durantel D, Zoulim F, Dumontet C (2013) Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. Nat Rev Drug Discovery 12: 447-464.
179. De Clercq E (2011) The clinical potential of the acyclic (and cyclic) nucleoside phosphonates: the magic of the phosphonate bond. Biochem Pharmacol 82: 99-109.
180. De Clercq E (2013) Highlights in antiviral drug research: antivirals at the horizon. Med Res Rev 33: 1215-1248.
181. Poijarvi-Virta P, Lonnberg H (2006) Prodrug approaches of nucleotides and oligonucleotides. Curr Med Chem 13: 3441-3465.
182. Hurwitz SJ, Schinazi RF (2013) Prodrug strategies for improved efficacy of nucleoside antiviral inhibitors. Curr Opin HIV AIDS 8: 556-564.
183. Miralles-Lluma R, Figueras A, Busque F, Alvarez-Larena A, Balzarini J, Figueredo M, Font J, Alibes R, Marechal J (2013) Synthesis, antiviral evaluation, and computational studies of cyclobutane and cyclobutene L-nucleoside analogues. Eur J Med Chem 2013: 7761-7775.
184. Oliveira FM, Barbosa LCA, Ismail FMD (2014) The diverse pharmacology and medicinal chemistry of phosphoramidates-a review. RSC Adv 4: 18998-19012.
185. Schulz T, Balzarini J, Meier C (2014) The DiPPro approach: synthesis, hydrolysis, and antiviral activity of lipophilic d4T diphosphate prodrugs. ChemMedChem 9: 762-775.
186. Jessen HJ, Schulz T, Balzarini J, Meier C (2008) Bioreversible protection of nucleoside diphosphates. Angew Chem Int Ed 47: 8719-8722.
187. Cho A, Zhang L, Xu J, Lee R, Butler T, Metobo S, Aktoudianakis V, Lew W, Ye H, ClarkeM et al (2014) Discovery of the first C-nucleoside HCV polymerase inhibitor (GS-6620) with demonstrated antiviral response in HCV infected patients. J Med Chem 57: 1812-1825.
188. Arbelo Roman C, Wasserthal P, Balzarini J, Meier C (2011) Diastereoselective synthesis of (aryloxy)phosphoramidate prodrugs. Eur J Org Chem 2011: 4899-4909.
189. Arbelo Roman C, Balzarini J, Meier C (2010) Diastereoselective synthesis of aryloxy phosphoramidate prodrugs of 3'-deoxy-2', 3'-didehydrothymidine monophosphate. J Med Chem 53: 7675-7681.
190. Sofia MJ, Bao D, Chang W, Du J, Nagarathnam D, Rachakonda S, Reddy PG, Ross BS, Wang P, Zhang HR et al (2010) Discovery of a beta-d-20-deoxy-20-alpha-fluoro-20-beta-Cmethyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J Med Chem 53: 7202-7218.
191. Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, Hindes RG, Berrey MM (2013) Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 368: 34-44.
192. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, Lawitz E, Lok AS, Hinestrosa F, Thuluvath PJ et al (2014) Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 370: 211-221.
193. Hazleton KZ, Ho M, Cassera MB, Clinch K, Crump DR, Rosario I, Merino EF, Almo SC, Tyler PC, Schramm VL (2012) Acyclic immucillin phosphonates: second-generation inhibitors of plasmodium falciparum hypoxanthine-guanine-xanthine phosphoribosyltransferase. Chem Biol 19: 721-730.
194. Keough DT, Spacek P, Hockova D, Tichy T, Vrbkova S, Slavetinska L, Janeba Z, Naesens L, Edstein MD, Chavchich Met al (2013) Acyclic nucleoside phosphonates containing a second phosphonate group are potent inhibitors of 6-oxopurine phosphoribosyltransferases and have antimalarial activity. J Med Chem 56: 2513-2526.
195. Keough DT, Hockova D, Rejman D, Spacek P, Vrbkova S, Krecmerova M, Eng WS, Jans H, West NP, Naesens LMJ et al (2013) Inhibition of the escherichia coli 6-oxopurine phosphoribosyltransferases by nucleoside phosphonates: potential for new antibacterial agents. J Med Chem 56: 6967-6984.
196. Ebetino FH, Hogan AL, Sun S, Tsoumpra MK, Duan X, Triffitt JT, Kwaasi AA, Dunford JE, Barnett BL, Oppermann U et al (2011) The relationship between the chemistry and biological activity of the bisphosphonates. Bone 49: 20-33.
197. Rogers MJ, Ji XH, Russell RGG, Blackburn GM, Williamson MP, Bayless AV, Ebetino FH, Watts DJ (1994) Incorporation of bisphosphonates into adenine-nucleotides by amebas of the cellular slime-mold dictyostelium-discoideum. Biochem J 303: 303-311.
198. Frith JC, Monkkonen J, Blackburn GM, Russell RGG, Rogers MJ (1997) Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 50-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res 12: 1358-1367.
199. Ahlmark M, Vepsalainen J, Taipale H, Niemi R, Jarvinen T (1999) Bisphosphonate prodrugs: synthesis and in vitro evaluation of novel clodronic acid dianhydrides as bioreversible prodrugs of clodronate. J Med Chem 42: 1473-1476.
200. Webster MR, Zhao M, Rudek MA, Hann CL, Freel Meyers CL (2011) Bisphosphonamidate clodronate prodrug exhibits potent anticancer activity in non-small-cell lung cancer cells. J Med Chem 54: 6647-6656.
201. Wiemer AJ, Hohl RJ, Wiemer DF (2009) The intermediate enzymes of isoprenoid metabolism as anticancer targets. Anticancer Agents Med Chem 9: 526-542.
202. Wiemer AJ, Wiemer DF, Hohl RJ (2011) Geranylgeranyl diphosphate synthase: an emerging therapeutic target. Clin Pharmacol Ther 90: 804-812.
203. Monteil M, Migianu-Griffoni E, Sainte-Catherine O, Di Benedetto M, Lecouvey M (2014) Bisphosphonate prodrugs: synthesis and biological evaluation in HuH7 hepatocarcinoma cells. Eur J Med Chem 77: 56-64.
204. Zhang Y, Leon A, Song Y, Studer D, Haase C, Koscielski LA, Oldfield E (2006) Activity of nitrogen-containing and non-nitrogen-containing bisphosphonates on tumor cell lines. J Med Chem 49: 5804-5814.
205. Wiemer AJ, Yu JS, Shull LW, Barney RJ, Wasko BM, Lamb KM, Hohl RJ, Wiemer DF (2008) Pivaloyloxymethyl-modified isoprenoid bisphosphonates display enhanced inhibition of cellular geranylgeranylation. Bioorg Med Chem 16: 3652-3660.
206. Troutman JM, Chehade KA, Kiegiel K, Andres DA, Spielmann HP (2004) Synthesis of acyloxymethyl ester prodrugs of the transferable protein farnesyl transferase substrate farnesyl methylenediphosphonate. Bioorg Med Chem Lett 14: 4979-4982.
207. Clark MK, Scott SA, Wojtkowiak J, Chirco R, Mathieu P, Reiners JJ Jr, Mattingly RR, Borch RF, Gibbs RA (2007) Synthesis, biochemical, and cellular evaluation of farnesyl monophosphate prodrugs as farnesyltransferase inhibitors. J Med Chem 50: 3274-3282.
208. Sane KM, Mynderse M, LaLonde DT, Dean IS, Wojtkowiak JW, Fouad F, Borch RF, Reiners JJ Jr, Gibbs RA, Mattingly RR (2010) A novel geranylgeranyl transferase inhibitor in combination with lovastatin inhibits proliferation and induces autophagy in STS-26 T MPNST cells. J Pharmacol Exp Ther 333: 23-33.
209. Wiemer AJ, Hsiao CH, Wiemer DF (2010) Isoprenoid metabolism as a therapeutic target in Gram-negative pathogens. Curr Top Med Chem 10: 1858-1871.
210. Reichenberg A, Wiesner J, Weidemeyer C, Dreiseidler E, Sanderbrand S, Altincicek B, Beck E, Schlitzer M, Jomaa H (2001) Diaryl ester prodrugs of FR900098 with improved in vivo antimalarial activity. Bioorg Med Chem Lett 11: 833-835.
211. Ortmann R, Wiesner J, Reichenberg A, Henschker D, Beck E, Jomaa H, Schlitzer M (2003) Acyloxyalkyl ester prodrugs of FR900098 with improved in vivo anti-malarial activity. Bioorg Med Chem 13: 2163-2166.
212. Ortmann R, Wiesner J, Reichenberg A, Henschker D, Beck E, Jomaa H, Schlitzer M (2005) Alkoxycarbonyloxyethyl ester prodrugs of FR900098 with improved in vivo antimalarial activity. Arch Pharm (Weinheim) 338: 305-314.
213. Kurz T, Schlueter K, Kaula U, Bergmann B, Walter RD, Geffken D (2006) Synthesis and antimalarial activity of chain substituted pivaloyloxymethyl ester analogues of fosmidomycin and FR900098. Bioorg Med Chem 14: 5121-5135.
214. Kurz T, Behrendt C, Kaula U, Bergmann B, Walter RD (2007) α-Phenylethyl substituted bis (pivaloyloxymethyl) ester analogs of fosmidomycin and FR900098. Aust J Chem 60: 154-158.
215. Schluter K, Walter RD, Bergmann B, Kurz T (2006) Arylmethyl substituted derivatives of fosmidomycin: synthesis and antimalarial activity. Eur J Med Chem 41: 1385-1397.
216. Kurz T, Schluter K, Pein M, Behrendt C, Bergmann B, Walter RD (2007) Conformationally restrained aromatic analogues of fosmidomycin and FR900098. Arch Pharm (Weinheim) 340: 339-344.
217. Haemers T, Wiesner J, Giessmann D, Verbrugghen T, Hillaert U, Ortmann R, Jomaa H, Link A, Schlitzer M, Van Calenbergh S (2008) Synthesis of beta-and gamma-oxa isosteres of fosmidomycin and FR900098 as antimalarial candidates. Bioorg Med Chem 16: 3361-3371.
218. Brucher K, Illarionov B, Held J, Tschan S, Kunfermann A, Pein MK, Bacher A, Graewert T, Maes L, Mordmueller B et al (2012) α-Substituted β-oxa isosteres of fosmidomycin: synthesis and biological evaluation. J Med Chem 55: 6566-6575.
219. Granthon AC, Braga MV, Rodrigues JCF, Cammerer S, Lorente SO, Gilbert IH, Urbina JA, de Wanderley S (2007) Alterations on the growth and ultrastructure of leishmania chagasi induced by squalene synthase inhibitors. Vet Parasitol 146: 25-34.
220. Uh E, Jackson ER, San Jose G, Maddox M, Lee RE, Lee RE, Boshoff HI, Dowd CS (2011) Antibacterial and antitubercular activity of fosmidomycin, FR900098, and their lipophilic analogs. Bioorg Med Chem Lett 21: 6973-6976.
221. Ponaire S, Zingle C, Tritsch D, Grosdemange-Billiard C, Rohmer M (2012) Growth inhibition of mycobacterium smegmatis by prodrugs of deoxyxylulose phosphate reductoisomerase inhibitors, promising anti-mycobacterial agents. Eur J Med Chem 51: 277-285.
222. Stankovic CJ, Surendran N, Lunney EA, Plummer MS, Para KS, Shahripour A, Fergus JH, Marks JS, Herrera R, Hubbell SE et al (1997) The role of 4-phosphonodifluoromethyl-and 4-phosphono-phenylalanine in the selectivity and cellular uptake of SH2 domain ligands. Bioorg Med Chem Lett 7: 1909-1914.
223. Garrido-Hernandez H, Moon KD, Geahlen RL, Borch RF (2006) Design and synthesis of phosphotyrosine peptidomimetic prodrugs. J Med Chem 49: 3368-3376.
224. Huang R, Oh H, Arrendale A, Martin VA, Galan J, Workman EJ, Stout JR, Walczak CE, Tao WA, Borch RF et al (2013) Intracellular targets for a phosphotyrosine peptidomimetic include the mitotic kinesin, MCAK. Biochem Pharmacol 86: 597-611.
225. Boutselis IG, Yu X, Zhang ZY, Borch RF (2007) Synthesis and cell-based activity of a potent and selective protein tyrosine phosphatase 1B inhibitor prodrug. J Med Chem 50: 856-864.
226. Auzenne EJ, Klostergaard J, Mandal PK, Liao WS, Lu Z, Gao F, Bast RC Jr, Robertson FM, McMurray JS (2012) A phosphopeptide mimetic prodrug targeting the SH2 domain of Stat3 inhibits tumor growth and angiogenesis. J Exp Ther Oncol 10: 155-162.
227. Mandal PK, Liao WSL, McMurray JS (2009) Synthesis of phosphatase-stable, cell-permeable peptidomimetic prodrugs that target the SH2 domain of Stat3. Org Lett 11: 3394-3397.
228. Mandal PK, Gao F, Lu Z, Ren Z, Ramesh R, Birtwistle JS, Kaluarachchi KK, Chen X, Bast RC, Liao WSL et al (2011) Potent and selective phosphopeptide mimetic prodrugs targeted to the Src homology 2 (SH2) domain of signal transducer and activator of transcription 3. J Med Chem 54: 3549-3563.
229. Mandal PK, Ren Z, Chen X, Kaluarachchi K, Liao WSL, McMurray JS (2013) Structureactivity studies of phosphopeptidomimetic prodrugs targeting the Src homology 2 (SH2) domain of signal transducer and activator of transcription 3 (Stat3). Int J Pept Res Ther 19: 3-12.
230. Morlacchi P, Mandal PK, McMurray JS (2014) Synthesis and in vitro evaluation of a peptidomimetic inhibitor targeting the Src homology 2 (SH2) domain of STAT6. ACS Med Chem Lett 5: 69-72.
231. Chu CY, Chang CP, Chou YT, Handoko HYL, Lo LC, Lin JJ (2013) Development and evaluation of novel phosphotyrosine mimetic inhibitors targeting the Src homology 2 domain of signaling lymphocytic activation molecule (SLAM) associated protein. J Med Chem 56: 2841-2849.
232. Arrendale A, Kim K, Choi JY, Li W, Geahlen RL, Borch RF (2012) Synthesis of a phosphoserine mimetic prodrug with potent 14-3-3 protein inhibitory activity. Chem Biol 19: 764-771.
233. Qian WJ, Burke TR Jr, Terrence R (2013) Design and synthesis of a reagent for solid-phase incorporation of the phosphothreonine mimetic (2S, 3R)-2-amino-3-methyl-4-phosphonobutyric acid (pmab) into peptides in a bio-reversible phosphonyl-bispivaloyloxymethyl (POM) prodrug form. Amino Acids 45: 1143-1148.